Key Drivers
- High Margins
- Strong Liquidity
- Rich Valuation
AIAI Summary
ResMed is evolving from a steady sleep-apnea compounder into a higher-quality cash-return story with strong margins, net cash, and aggressive buybacks, but with FY27 growth normalizing and valuation already rich, the key takeaway is to stay constructive only if it can prove mid-single-digit growth is conservative rather than structural.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Liquidity
- •Rich Valuation
RMD delivers strong margins, returns, liquidity, and cash flow with modest leverage, but its rich valuation and sizable intangible assets limit downside protection.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Fast rebound
- •Near resistance
RMD remains in a short-term uptrend, with higher highs/lows and a quick rebound from the Aug. 7 dip, but it is now testing resistance near $226.74 and must hold $220-$223 to keep the bullish setup intact.
Sharp
Sentiment & News
Key News Insights:
- •Record Revenue
- •Strong Demand
- •Softer Outlook
ResMed posted a strong fiscal Q4 beat with record revenue and EPS, but the stock fell as softer FY2027 guidance and cost headwinds overshadowed the solid current demand trend.
The earnings strength supports the long-term case, but near-term share performance may stay pressured until guidance and margin concerns ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings